Possible therapeutic potential of a recombinant group 2 grass pollen allergen-specific antibody fragment

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 2, 2014, Pages 261-264

  Gadermaier, E ^a   Flicker, S ^a   Blatt, K ^a   Valent, P ^a   Valenta, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

allergy; grass pollen; recombinant single chain fragment; therapy

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; POLLEN ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNTHETIC DNA; TIMOTHY GRASS POLLEN ALLERGEN PHL P 2; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; BASOPHIL; BASOPHIL DEGRANULATION; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE EXPRESSION; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; PHLEUM PRATENSE; POLLEN ALLERGY; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

ALLERGY; GRASS POLLEN; RECOMBINANT SINGLE-CHAIN FRAGMENT; THERAPY;

ALLERGENS; ANTIBODY AFFINITY; DESENSITIZATION, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; PLANT PROTEINS; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE;

EID: 84893068698     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12315     Document Type: Article

References (14)

1. Suphioglu C,. What are the important allergens in grass pollen that are linked to human allergic disease? Clin Exp Allergy 2000; 30: 1335-1341.
2. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-475. (Pubitemid 29372886)
3. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33: 1198-1208. (Pubitemid 37108522)
4. Gadermaier E, Staikuniene J, Scheiblhofer S, Thalhamer J, Kundi M, Westritschnig K, et al. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation. Allergy 2011; 66: 1174-1182.
5. Westritschnig K, Horak F, Swoboda I, Balic N, Spitzauer S, Kundi M, et al. Different allergenic activity of grass pollen allergens revealed by skin testing. Eur J Clin Invest 2008; 38: 260-267. (Pubitemid 351389144)
6. Niederberger V, Stubner P, Spitzauer S, Kraft D, Valenta R, Ehrenberger K, et al. Skin test results but not serology reflect immediate type respiratory sensitivity: a study performed with recombinant allergen molecules. J Invest Dermatol 2001; 117: 848-851. (Pubitemid 33001200)
7. Flicker S, Steinberger P, Norderhaug L, Sperr WR, Majlesi Y, Valent P, et al. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol 2002; 32: 2156-2162. (Pubitemid 34965878)
8. Padavattan S, Flicker S, Schirmer T, Madritsch C, Randow S, Reese G, et al. High-affinity IgE recognition of a conformational epitope of the major respiratory allergen Phl p 2 as revealed by X-ray crystallography. J Immunol 2009; 182: 2141-2151.
9. Beck A, Wurch T, Bailly C, Corvaia N,. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10: 345-352.
10. Levin M, Ohlin M,. Inconclusive evidence for or against positive antigen selection in the shaping of human immunoglobulin E repertoires: a call for new approaches. Int Arch Allergy Immunol 2013; 161: 122-126.
11. Gadermaier E, Levin M, Flicker S, Ohlin M,. The human IgE repertoire. Int Arch Allergy Immunol 2013; 163: 77-91.
12. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WR, et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002; 110: 102-109. (Pubitemid 36132735)
13. Strait RT, Morris SC, Finkelman FD,. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest 2006; 116: 833-841. (Pubitemid 43326893)
14. Kontermann RE,. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011; 22: 868-876.